RxDoctor Payments Data

Sonia Canaves Nunez, MD

Neurology · Jupiter, FLNPI 1437184843

Payments from drug & device makers

$11,010in general payments, 2019–2025

Across 574 payments — averaging $19.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$971
  • Teva Pharmaceuticals USA, Inc.$770
  • Sanofi$638
  • Biogen$585
  • Neurocrine Biosciences, Inc.$544
  • plus $6K from 50 others

What the payments were for

  • Food & beverage$10,996100%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,010 in reported general payments places this provider in the 65th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$114,121
Medicare patients
404
Services billed
820

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4615$207,896
NeuproRotigotine16$19,908
Emgality PenGalcanezumab-Gnlm20$16,812
Glatiramer Acetate11$15,607
Gabapentin114$3,141
Memantine Hcl117$2,882
Lacosamide31$2,481
Diazepam18$2,231
Carbidopa-LevodopaCarbidopa/Levodopa105$2,049
Teriflunomide48$1,957
Carbidopa-Levodopa ErCarbidopa/Levodopa42$1,842
Donepezil Hcl133$1,767
Oxcarbazepine12$1,169
Levetiracetam47$1,119
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen22$1,112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$103$207,89615 claims
UCB, Inc.Neupro$530$19,90816 claims
Upsher-smith Laboratories LLCTopiramate$71$24918 claims
Almatica Pharma LLCSertraline Hcl$44$8615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,434 neurology providers in Florida.

Other neurology in Jupiter

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →